Driving Value in the Evolution Toward Continuous Monoclonal Antibody Processing
June 7, 2018 - Bedford MA USMilliporeSigma
Eddie.Liao@emdmillipore.com
Phone:781-533-5708
With intensification of upstream and downstream processes, several scenarios for Mab production become apparent. We will identify these scenarios with process modeling data to quantify the financial benefits and holistic value of these technologies. The biopharmaceutical industry is adopting a more strategic view toward monoclonal antibody manufacturing. There is a drive to develop processes with higher productivity and improved economics without sacrificing robustness or quality. Initiatives to achieve these goals through unit operation intensification, connected processing, and continuous processing have been a major focus and this trend will only accelerate. Opportunities for process intensification exist throughout the entire monoclonal antibody process. With the implementation of perfusion-based operations from seed train to production bioreactors, and downstream technologies such as intensified capture chromatography, in-line virus inactivation, and flow-through polishing, a variety of scenarios for Mab production trains become apparent. In this presentation, we will identify several of these production scenarios with process modeling data to quantify the financial benefits and holistic value derived from the integration and intensification of Mab processes.